Vivani Medical, Inc.
VANI
Positions held
Your positionsVANI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $110.95M | Enterprise value | $108.91M | Trailing P/E | — | Forward P/E | -3.51 |
| PEG | — | Price / book | 5.80 | Beta | 3.30 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.2% | ROA | -48.5% | Debt / equity | 0.94 |
| Current ratio | 3.25 | Free cash flow | -$16.83M | Analyst recommendation | none | Mean target | $3.83 |
| 52w high | $1.92 | 52w low | $0.92 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.4M | -$6.8M | -$6.6M | -$6.5M | -$7.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.9M | -$6.8M | -$6.8M | -$6.7M | -$7.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$26.6M | -$23.5M | -$25.7M | -$13.9M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$27.6M | -$24.7M | -$27.0M | -$21.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-03 · Vivani Medical Announces Participation in Upcoming Investor Conferences
2026-08-29 · Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
2026-08-13 · Vivani Medical: Q2 Earnings Snapshot
2026-08-13 · Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 · Top Midday Gainers
2026-08-06 · Vivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial
2026-08-06 · Top Premarket Gainers
2026-07-16 · Vivani Medical Insider Bought Shares Worth $999,999, According to a Recent SEC Filing
2026-07-15 · Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
2026-07-14 · Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
2026-07-14 · Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream
Price (daily)
Full chart · RSI · MACD · patterns